Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Duesseldorf, Germany.
Orphanet J Rare Dis. 2013 Aug 7;8:119. doi: 10.1186/1750-1172-8-119.
Congenital generalized lipodystrophy (CGL) or Berardinelli-Seip congenital lipodystrophy (BSCL) is a rare genetic syndrome characterized by the absence of adipose tissue. As CGL is thought to be related to malfunctions in adipocyte development, genes involved in the mechanisms of adipocyte biology and maintenance or differentiation of adipocytes, especially transcription factors are candidates. Several genes (BSCL1-4) were found to be associated to the syndrome but not all CGL patients carry mutations in these genes.
In a patient with CGL and insulin resistance we investigated the known candidate genes but the patient did not carry a relevant mutation. Analyses of the insulin activated signal transduction pathways in isolated fibroblasts of the patient revealed a postreceptor defect altering expression of the immediate early gene c-fos. Sequence analyses revealed a novel homozygous point mutation (c.-439, T→A) in the patients' c-fos promoter. The point mutation was located upstream of the well characterized promoter elements in a region with no homology to any known cis-elements. The identified mutation was not detected in a total of n=319 non lipodystrophic probands. In vitro analyses revealed that the mutation facilitates the formation of a novel and specific protein/DNA complex. Using mass spectrometry we identified the proteins of this novel complex. Cellular investigations demonstrate that the wild type c-fos promoter can reconstitute the signaling defect in the patient, excluding further upstream signaling alterations, and vice versa the investigations with the c-fos promoter containing the identified mutation generally reduce basal and inducible c-fos transcription activity. As a consequence of the identified point mutation gene expression including c-Fos targeted genes is significantly altered, shown exemplified in cells of the patient.
The immediate-early gene c-fos is one essential transcription factor to initiate adipocyte differentiation. According to the role of c-fos in adipocyte differentiation our findings of a mutation that initiates a repression mechanism at c-fos promoter features the hypothesis that diminished c-fos expression might play a role in CGL by interfering with adipocyte development.
先天性全身性脂肪营养不良(CGL)或 Berardinelli-Seip 先天性脂肪营养不良(BSCL)是一种罕见的遗传综合征,其特征是脂肪组织缺失。由于 CGL 被认为与脂肪细胞发育的功能障碍有关,因此涉及脂肪细胞生物学机制和脂肪细胞的维持或分化的基因,特别是转录因子是候选基因。已经发现几个基因(BSCL1-4)与该综合征有关,但并非所有 CGL 患者的这些基因都携带突变。
在一名 CGL 伴胰岛素抵抗的患者中,我们研究了已知的候选基因,但患者未携带相关突变。对患者分离的成纤维细胞中胰岛素激活的信号转导途径的分析显示,受体后缺陷改变了即刻早期基因 c-fos 的表达。序列分析显示,患者的 c-fos 启动子中存在一个新的纯合点突变(c.-439,T→A)。该点突变位于已明确的启动子元件上游,位于与任何已知顺式元件无同源性的区域。该鉴定的突变未在总共 n=319 名非脂肪营养不良的对照者中检测到。体外分析显示,该突变促进了一种新型和特异的蛋白质/DNA 复合物的形成。使用质谱法,我们鉴定了该新型复合物的蛋白质。细胞研究表明,野生型 c-fos 启动子可以在患者中重建信号缺陷,排除了进一步的上游信号改变,反之亦然,用含有鉴定突变的 c-fos 启动子进行的研究通常会降低基础和诱导型 c-fos 转录活性。由于鉴定的点突变,包括 c-Fos 靶向基因的基因表达发生显著改变,在患者的细胞中举例说明了这一点。
即刻早期基因 c-fos 是启动脂肪细胞分化的一个重要转录因子。根据 c-fos 在脂肪细胞分化中的作用,我们发现的启动子突变起始了一种抑制机制,这一发现支持了这样的假设,即 c-fos 表达的减少可能通过干扰脂肪细胞发育在 CGL 中发挥作用。